Shares of Intellia Therapeutics, Inc. (NTLA) were down 4.5% on Jun 26 after it announced that its current chief financial officer (CFO), Glenn Goddard, is stepping down from his role effective Jun 30, 2024.The company has appointed Edward Dulac as its new CFO, executive vice president and treasurer. He will assume his new role with effect from Jul 22, 2024.Dulac most recently served as the CFO of Fate Therapeutics. He previously held senior leadership positions at Celgene (now part of Bristol Myers) and als ...